Valo Therapeutics(AVTX)

Focus: Valo Therapeutics is a publicly traded biotech company focused on oncolytic virus and peptide therapeutics for ophthalmology and oncology indications. The company is in early-stage development with minimal revenue generation and significant R&D investment.

Ophthalmology Oncology

Profile data last refreshed 2h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Valo Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Valo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$441K

Pipeline & Clinical Trials

PeptiCRAd-1

Melanoma (Skin)

PHASE_1

Clinical Trials (1)

NCT05492682START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1

Help build intelligence for Valo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to emerging modalities (oncolytic virus, peptide therapeutics) with potential for significant clinical upside if Phase 2 programs succeed
Public company status provides equity liquidity and potential for significant value creation if pipeline programs advance
Focused pipeline in high-value therapeutic areas (oncology, ophthalmology) with unmet medical needs

Watch Out For

Severe cash burn ($35M net loss in FY 2025) with minimal revenue ($441K) creates near-term sustainability risk despite $135M cash position
Zero active job openings at time of analysis indicates potential hiring freeze or organizational constraints
Only 3 pipeline programs with highest phase being Phase 2, suggesting limited near-term catalysts and extended path to potential revenue

Generated by Claude from Valo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

OPL-0401 Dose 1

Non-proliferative Diabetic Retinopathy

PHASE_2

Clinical Trials (1)

NCT05393284Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Phase 2

OPL-0301 Dose 1

Myocardial Infarction

PHASE_2

Clinical Trials (1)

NCT05327855Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$441K77%

R&D Spend

$24M(5541%)77%

Net Income

-$35M